Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 6Unknown 1Not yet recruiting 1No longer available 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 5Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Pleural Effusion, Malignant 1Neoplasm, Residual 1NSCLC 1Lung Neoplasms 1

Interventions

pembrolizumab 563Specimen Handling 493Carboplatin 451Magnetic Resonance Spectroscopy 444Cyclophosphamide 418Cisplatin 405Radiotherapy 353Bevacizumab 314Gemcitabine 313Paclitaxel 298Biopsy 292Drug Therapy 284Blood Specimen Collection 248Capecitabine 246Oxaliplatin 241fludarabine 239Nivolumab 234venetoclax 221Injections 213Docetaxel 211Fluorouracil 206Dexamethasone 188Radiosurgery 182Standard of Care 159Rituximab 159Pemetrexed 156Surgical Procedures, Operative 148atezolizumab 146durvalumab 145Leucovorin 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × sugemalimab × Clear all
NCT06097962 2026-05-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting
12 enrolled
Thoracic

Pleural Effusion, Malignant

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Sichuan University

Phase 1/2 Recruiting
45 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT07247227 2025-11-25

Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC

Peking Union Medical College

Phase NA Recruiting
150 enrolled
Thoracic

NSCLC

NCT06617416 2025-03-12

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Akeso

Phase 3 Recruiting
560 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05623267 2023-08-07

SURPASS

Sun Yat-sen University

Phase 2/3 Recruiting
346 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT05940532 2023-07-11

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

Hunan Cancer Hospital

Phase 2 Recruiting
41 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡